Pharmaceutical Technology - November 2018

Pharmaceutical Technology - eBook

Issue link:

Contents of this Issue


Page 17 of 45

18 Pharmaceutical Technology LABORATORY BEST PRACTICES 2018 P h a r mTe c h . c o m Analytical Methods • Ensuring that all data supporting the assay de- velopment are reviewed and verifiable • Ensuring that data reduction is based on trans- parent and sound calculations • Making sure that documentation supporting the method development is captured in real time • Making sure that development details are leg- ible, if captured on paper, complete, and easy to follow. If the development of an analytical method is to be pursued based on the QbD concept, as it is strongly recommended, one needs to follow the multiple discrete steps outlined in Figure 1. Unlike the traditional analytical method de- velopment approach, where method variables are Figure 1: Diagram of method development by quality by design (QbD). DoE is design of experiment. Table I: Analytical methods and product quality attributes. Product attribute Analytical methods Identity N-terminal sequencing, peptide mapping, enzyme-linked immunosorbent assay (ELISA), Western blot, high- performance liquid chromatography (HPLC), electrophoresis Aggregation High performance/ultra performance size exclusion chromatography (HP/UP-SEC), analytical ultracentrifugation (AUC), field-flow fractionation (FFF) Purity Reverse-phase (RP)-HPLC, hydrophobic interaction chromatography (HIC), capillary electrophoresis sodium dodecyl sulfate (CE-SDS), Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) Strength Absorbance, colorimetric assay, ELISA Potency Cell-based assay, ELISA, surface plasmon resonance (SPR)` Particulates Light obscuration (HIAC), microfluidic imaging (MFI), Coulter counter FIGURES COURTESY OF THE AUTHOR

Articles in this issue

Links on this page

Archives of this issue

view archives of Pharmaceutical Technology - November 2018 - Pharmaceutical Technology - eBook